Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets

Fineline Cube Jun 2, 2026
Company Deals

Simcere Pharmaceutical Secures Exclusive Rights to PrimeGenX’s Pumecitinib Gel for Atopic Dermatitis in Greater China

Fineline Cube Jun 2, 2026
Company Deals

Servier Group Acquires Edgewise Therapeutics’ Muscular Dystrophy Business for Up to $2.65 Billion

Fineline Cube Jun 2, 2026
Company Deals

HemaCell Therapeutics Secures $44 Million Series B to Advance World’s First Megakaryocyte Injection for Platelet Regeneration

Fineline Cube Jun 2, 2026
Company Deals

Haisco Pharmaceutical and Eli Lilly Forge $3 Billion Drug Discovery Alliance Spanning Multiple Therapeutic Areas

Fineline Cube Jun 2, 2026
Policy / Regulatory

China’s NMPA Introduces Comprehensive Medical Device Classification Reforms with 2-5 Year Transitional Periods

Fineline Cube Jun 2, 2026
Company Drug

Amgen’s Tarlatamab Receives EC Approval for Extensive-Stage SCLC with 40% Mortality Reduction in Phase III Trial

Fineline Cube Jun 2, 2026
Company Drug

Alphamab Oncology’s HER3×TROP2 Bispecific ADC JSKN016 Shows 64.5% Response Rate in Triple-Negative Breast Cancer at ASCO 2026

Fineline Cube Jun 2, 2026
Company Medical Device

Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction

Fineline Cube Apr 24, 2026

Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received marketing approval from China’s National...

Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026

Sisram Medical Ltd (HKG: 1696), an Israel-based aesthetic medical technology company and subsidiary of Fosun...

Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026

China Medical System Holdings Limited (CMS; HKG: 0867) announced that the National Medical Products Administration...

Company Drug

AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested

Fineline Cube Apr 24, 2026

AbbVie Inc. (NYSE: ABBV) disclosed on April 23, 2026, that it has received a Complete...

Company Drug

Regeneron Secures FDA Approval for Otarmeni Gene Therapy and Announces Landmark U.S. Pricing Agreement

Fineline Cube Apr 24, 2026

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has...

Company

Thermo Fisher Scientific Reports 6% Revenue Growth in Q1 2026 Driven by Innovative Product Launches and Strategic AI Collaboration

Fineline Cube Apr 24, 2026

Thermo Fisher Scientific Inc. (NYSE: TMO) announced first-quarter 2026 financial results with revenue growing 6%...

Others

China’s National Health Commission Proposes Sweeping Reforms to Narcotics and Psychotropic Drugs Management Framework

Fineline Cube Apr 24, 2026

China’s National Health Commission (NHC) released a draft notification for public consultation on comprehensive revisions...

Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026

SciClone Pharmaceuticals Inc (HKG: 6600) announced a strategic partnership agreement with JD Healthcare (HKG: 6618),...

Company

Roche Q1 Sales Rise 6% Driven by Innovative Medicines as China Expansion and Diagnostics Recovery Offset Currency Headwinds

Fineline Cube Apr 24, 2026

Roche AG (SWX: ROP, OTCMKTS: RHHBY) reported first-quarter 2026 group sales of CHF 14.7 billion...

Company Drug

Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026

Fineline Cube Apr 23, 2026

Transcenta Holdings Ltd (HKG: 6628) has presented pre-clinical data for its proprietary LIV1 antibody-drug conjugate...

Company Drug

Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month

Fineline Cube Apr 23, 2026

Simcere Pharmaceutical Group Limited (HKG: 2096) has withdrawn its New Drug Application (NDA) for rademikibart...

Company

Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals

Fineline Cube Apr 23, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has released its first quarter 2026...

Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026

Sipai Health Technology Co., Ltd. (HKG: 0314), also known as Mebanks, has announced the sale...

Company Drug

Kangtai Biological Initiates Phase I Clinical Study for Trivalent Influenza Split Vaccine Produced in MDCK Cells

Fineline Cube Apr 23, 2026

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has announced the initiation of a single-center,...

Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026

AbbVie (NYSE: ABBV) has announced plans to invest $1.4 billion to construct a state-of-the-art pharmaceutical...

Company Deals Digital

Merck & Co. Announces $1 Billion Strategic Partnership with Google Cloud to Deploy Enterprise-Wide Agentic AI Platform

Fineline Cube Apr 23, 2026

Merck & Co., Inc. (MSD, NYSE: MRK) has announced a multi-year strategic partnership with Google...

Company Drug

FDA Expands Sanofi’s Tzield Approval to Children as Young as One Year Old for Type 1 Diabetes Prevention

Fineline Cube Apr 23, 2026

The U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application for...

Company

Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance

Fineline Cube Apr 23, 2026

Boston Scientific Corporation (NYSE: BSX) has released its first quarter 2026 financial results, reporting group...

Company Drug

European Commission Grants Conditional Approval to Ipsen’s Ojemda (Tovorafenib) for Pediatric Low-Grade Glioma with BRAF Alterations

Fineline Cube Apr 23, 2026

Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced on April 22, 2026, that the European Commission...

Company Medical Device

Johnson & Johnson Secures CE Mark for Advanced ETHICON 4000 Surgical Stapler with Proprietary 3D Stapling Technology

Fineline Cube Apr 23, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced on April 22, 2026, that it has received...

Posts pagination

1 … 20 21 22 … 676

Recent updates

  • China’s NMPA Introduces Comprehensive Medical Device Classification Reforms with 2-5 Year Transitional Periods
  • Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets
  • Simcere Pharmaceutical Secures Exclusive Rights to PrimeGenX’s Pumecitinib Gel for Atopic Dermatitis in Greater China
  • Amgen’s Tarlatamab Receives EC Approval for Extensive-Stage SCLC with 40% Mortality Reduction in Phase III Trial
  • Servier Group Acquires Edgewise Therapeutics’ Muscular Dystrophy Business for Up to $2.65 Billion
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s NMPA Introduces Comprehensive Medical Device Classification Reforms with 2-5 Year Transitional Periods

Company Deals

Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets

Company Deals

Simcere Pharmaceutical Secures Exclusive Rights to PrimeGenX’s Pumecitinib Gel for Atopic Dermatitis in Greater China

Company Drug

Amgen’s Tarlatamab Receives EC Approval for Extensive-Stage SCLC with 40% Mortality Reduction in Phase III Trial

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.